{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:52:31Z","timestamp":1767135151768,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011772.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:00:00Z","timestamp":1604793600000}}],"reference-count":50,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011772.pub3","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T04:26:25Z","timestamp":1605155185000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rufinamide add-on therapy for drug-resistant epilepsy"],"prefix":"10.1002","author":[{"given":"Mariangela","family":"Panebianco","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology; Institute of Translational Medicine, University of Liverpool; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemanshu","family":"Prabhakar","sequence":"additional","affiliation":[{"name":"Department of Neuroanaesthesiology and Critical Care; All India Institute of Medical Sciences; New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology; Institute of Translational Medicine, University of Liverpool; Liverpool UK"},{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Liverpool Health Partners; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,8]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD011772.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1528-1167.2010.02729.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures","volume":"52","author":"Biton","year":"2011","journal-title":"Epilepsia"},{"issue":"7","key":"10.1002\/14651858.CD011772.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1528-1167.2006.00589.x","article-title":"The effect of the new antiepileptic drug rufinamide on cognitive functions","volume":"47","author":"Aldenkamp","year":"2006","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0003|cit3","first-page":"171, Abstract n","article-title":"Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures","volume":"46 Suppl 8","author":"Brodie","year":"2005","journal-title":"Epilepsia"},{"issue":"8","key":"10.1002\/14651858.CD011772.pub3-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/j.1528-1167.2009.02160.x","article-title":"Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial","volume":"50","author":"Brodie","year":"2009","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0005|cit5","first-page":"140, Abstract n","article-title":"Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures","volume":"47 Suppl 3","author":"Rosenfeld","year":"2006","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0006|cit6","first-page":"255, Abstract n","article-title":"Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy-resistant partial-onset seizures","volume":"41 Suppl 7","author":"Vazquez","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0007|cit7","first-page":"83","article-title":"Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures","volume":"46 Suppl 8","author":"Elger","year":"2005","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0008|cit8","first-page":"140, Abstract n","article-title":"Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures","volume":"47 Suppl 3","author":"Elger","year":"2006","journal-title":"Epilepsia"},{"issue":"2-3","key":"10.1002\/14651858.CD011772.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.eplepsyres.2009.12.003","article-title":"A 24-week multicenter, randomized, double-blind, parallel-group, dose ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures","volume":"88","author":"Elger","year":"2010","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0010|cit10","first-page":"39","article-title":"A multicenter double-blind randomized placebo-controlled 5-arm, parallel-group trial of rufinamide in patients with therapy-resistant partial seizures","volume":"41 Suppl Floren","author":"Stefan","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0011|cit11","first-page":"194","article-title":"Efficacy and safety of rufinamide as adjunctive therapy for inadequately controlled partial seizures in pediatric patients","volume":"46 Suppl 8","author":"Glauser","year":"2005","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0012|cit12","first-page":"156, Abstract n","article-title":"Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study","volume":"48 Suppl 7","author":"Glauser","year":"2007","journal-title":"Epilepsia"},{"issue":"21","key":"10.1002\/14651858.CD011772.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox-Gastaut Syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0014|cit14","first-page":"S92, Abstract n","article-title":"Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome","volume":"58 Suppl 9","author":"Glauser","year":"2005","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD011772.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1826, Abstract","DOI":"10.1212\/WNL.64.10.1826","article-title":"Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial","volume":"64","author":"Glauser","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0016|cit16","first-page":"261, Abstract n","article-title":"Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome","volume":"50 Suppl 11","author":"Glauser","year":"2009","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0017|cit17","first-page":"139, Abstract n","article-title":"Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome","volume":"47 Suppl 3","author":"Kluger","year":"2006","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0018|cit18","first-page":"359, Abstract n","article-title":"Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome","volume":"48 Suppl 6","author":"Krauss","year":"2007","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD011772.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40120-016-0041-9","article-title":"Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety\/tolerability of rufinamide","volume":"5","author":"McMurray","year":"2016","journal-title":"Neurology & Therapy"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.01.002","article-title":"Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial","volume":"121","author":"Ohtsuka","year":"2016","journal-title":"Epilepsy Research"},{"issue":"9","key":"10.1002\/14651858.CD011772.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.eplepsyres.2014.08.019","article-title":"Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan","volume":"108","author":"Ohtsuka","year":"2014","journal-title":"Epilepsy Research"},{"issue":"3","key":"10.1002\/14651858.CD011772.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/11313640-000000000-00000","article-title":"The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK","volume":"28","author":"Benedict","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1002\/14651858.CD011772.pub3-BIB0023|cit23","first-page":"206","article-title":"Efficacy and safety of adjunctive rufinamide in patients with inadequately controlled primary generalized tonic-clonic seizures","volume":"46","author":"Biton","year":"2005","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0024|cit24","first-page":"209","article-title":"Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox-Gastaut syndrome","volume":"46 Suppl 8","author":"Critchley","year":"2005","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD011772.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.seizure.2012.02.006","article-title":"Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome","volume":"21","author":"Kim","year":"2012","journal-title":"Seizure"},{"issue":"1","key":"10.1002\/14651858.CD011772.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/nedt.2007.3.1.3","article-title":"Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)","volume":"3","author":"Kluger","year":"2007","journal-title":"Neuropsychiatric Disease & Treatment"},{"issue":"11","key":"10.1002\/14651858.CD011772.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/epi.13557","article-title":"Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort","volume":"57","author":"Knupp","year":"2016","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0028|cit28","first-page":"177","article-title":"Efficacy and safety of rufinamide monotherapy for treatment of patients with refractory partial seizures","volume":"46 Suppl 8","author":"Lesser","year":"2005","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0029|cit29","first-page":"278","article-title":"Efficacy of rufinamide in epileptic encephalopathies secondary to complex brain malformations","volume":"145","author":"Madeddu","year":"2013","journal-title":"Bollettino - Lega Italiana Contro l'Epilessia"},{"issue":"2","key":"10.1002\/14651858.CD011772.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0920-1211(00)00185-6","article-title":"Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy","volume":"43","author":"Palhagen","year":"2001","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0031|cit31","first-page":"149","article-title":"Population pharmacokinetics and drug-drug interactions of rufinamide in a multicenter, double-blind, randomized, placebo-controlled, 5-arm parallel trial in patients with partial seizures on up to three concomitant antiepileptic drugs","volume":"41 Suppl","author":"Racine","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0032|cit32","first-page":"218","article-title":"Efficacy and safety of high-versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures","volume":"46 Suppl 8","author":"Todorov","year":"2005","journal-title":"Epilepsia"},{"issue":"5","key":"10.1002\/14651858.CD011772.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s13318-015-0291-4","article-title":"Pharmacokinetics and tolerability of rufinamide following single and multiple oral doses and effect of food on pharmacokinetics in healthy Chinese subjects","volume":"41","author":"Xu","year":"2016","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"issue":"3","key":"10.1002\/14651858.CD011772.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejpn.2015.12.015","article-title":"Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study","volume":"20","author":"Arzimanoglou","year":"2016","journal-title":"European Journal of Paediatric Neurology: EJPN"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2147\/NDT.S13910","article-title":"Update on rufinamide in childhood epilepsy","volume":"7","author":"Coppola","year":"2011","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0036|cit36","unstructured":"Hamilton (ON): McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"issue":"12","key":"10.1002\/14651858.CD011772.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1586\/ern.09.114","article-title":"Management of the patient with medically refractory epilepsy","volume":"9","author":"Granata","year":"2009","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0038|cit38","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"issue":"3","key":"10.1002\/14651858.CD011772.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1756285613481083","article-title":"Efficacy and safety of rufinamide in pediatric epilepsy","volume":"6","author":"Hsieh","year":"2013","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"4","key":"10.1002\/14651858.CD011772.pub3-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1528-1157.1993.tb00433.x","article-title":"Guidelines for epidemiologic studies on epilepsy","volume":"34","author":"ILAE Commission on Epidemiology and Prognosis","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4. Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6. Cochrane, 2019 Available from training.cochrane.org\/handbook\/supplementary-materials","DOI":"10.1002\/9781119536604.ch4"},{"issue":"4","key":"10.1002\/14651858.CD011772.pub3-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002896.pub2","article-title":"Vagus nerve stimulation for partial seizures","author":"Panebianco","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0044|cit44","unstructured":"The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3 2014"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0045|cit45","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013) GRADE Working Group. Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"11","key":"10.1002\/14651858.CD011772.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in literature","volume":"53","author":"Sterne","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011772.pub3-BIB0047|cit47","first-page":"1158","article-title":"Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of seven clinical trials","volume":"50","author":"Wheless","year":"2009","journal-title":"Journal of Child Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011772.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1535-7511.2009.01336.x","article-title":"Rufinamide: a novel broad-spectrum antiepileptic drug","volume":"10","author":"Wheless","year":"2010","journal-title":"Epilepsy Currents"},{"issue":"6","key":"10.1002\/14651858.CD011772.pub3-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011772","article-title":"Rufinamide add-on therapy for refractory epilepsy","author":"Panebianco","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011772.pub3-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011772.pub2","article-title":"Rufinamide add-on therapy for refractory epilepsy","author":"Panebianco","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T15:19:51Z","timestamp":1669562391000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011772.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,8]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011772.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,8]]}}}